Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
18 evidence topics · 18 sources
Bladder cancer mortality in the United States
Five-year relative survival overall and for in situ disease
Recurrence, progression, and bladder cancer mortality after high-grade NMIBC, SEER-Medicare
“Of 7,410 subjects, 2,897 (39.1%) experienced a recurrence without progression, 2,449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using competing-risks regression analysis, we found the 10-year recurrence, progression, and bladder cancer-related mortality rates to be 74.3%, 33.3%, and 12.3%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly three-fourths of patients diagnosed with high-risk bladder cancer will recur, progress, or die within ten years of their diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Probability of progression at five years by prognostic risk group
“From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk of progression and metastasis after BCG failure
Survival with BCG-unresponsive high-risk NMIBC, SEER-Medicare model input
BCG-refractory compared with BCG-relapsing disease, prospective cohort
“Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression and disease-specific death after T1 recurrence following BCG
“In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence and progression with bladder-sparing therapy in BCG-unresponsive NMIBC, international multicenter cohort
“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival in BCG-unresponsive NMIBC, single-center registry
“In total, 114 patients with a median follow-up of 71.2 mo (interquartile range: 32.6–132.2) were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no significant differences in OS (hazard ratio [HR]: 1.40, 95% confidence interval [CI]: 0.68–2.89, p = 0.4) or CSS (HR: 0.88, 95% CI: 0.22–3.55, p = 0.9) between patients undergoing early RC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 60 mo, BST patients had a high-grade recurrence-free rate, muscle-invasive disease/metastasis progression-free rate, and avoidance of RC rate of 37%, 83%, and 58%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence, progression, and cystectomy after BCG, US electronic health record and claims cohort
Outcomes in BCG-exposed high-grade NMIBC not meeting the unresponsive definition, single-center cohort
“In the BCG-E group, 50.2% experienced recurrence and 15.5% experienced progression; median recurrence-free survival (RFS) was 27.2 mo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-yr survival rate estimates were 32.25% for RFS, 79.3% for progression-free survival (PFS), 84.5% for metastasis-free survival (MFS), and 65.0% for overall survival (OS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical outcomes within 12 months of high-grade recurrence after BCG, prospective CISTO cohort
“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 12 months, 27 (8.1%) participants in the BST arm underwent an eventual RC, including 21 (6.3%) for recurrent high-grade NMIBC and four (1.2%) for progression to MIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because 22% of patients undergoing RC had pathology demonstrating MIBC, 12-month progression-free survival (PFS) was lower for RC (73% v 92% for BST; wRR, 0.81 [95% CI, 0.74 to 0.88];” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival after radical cystectomy for BCG failure
“We retrospectively analyzed the records of 117 patients who underwent radical cystectomy for recurrent nonmuscle invasive bladder cancer at our institution from 1990 to 2012.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Salvage radical cystectomy compared with BCG rechallenge in BCG-unresponsive NMIBC, Japanese multicenter databases
“In the adjusted BCG-unresponsive NMIBC cohort, no differences in MFS or OS were detected (p = 0.76 and p = 0.35, respectively), although long-term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote